Caribou Biosciences, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Rachel E. Haurwitz and CFO Sriram Ryali certify the 10-Q for the period ended June 30, 2026, confirming the financial statements fairly present the company's financial condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud are disclosed. The certifications are routine periodic SOX compliance documents.
Why this rating
Standard Sarbanes-Oxley certification exhibit; routine quarterly filing requirement. No operational, financial, or strategic changes disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.